Loading clinical trials...
Loading clinical trials...
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon
Conditions
Interventions
MQX-503
Locations
1
United States
Rainier Clinical Research
Renton, Washington, United States
Start Date
July 1, 2006
Completion Date
July 1, 2006
Last Updated
May 30, 2007
NCT02396238
NCT01090492
NCT02615964
NCT00048763
Lead Sponsor
MediQuest Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions